RTW INVESTMENTS, LP Reduces Stake in Taysha Gene Therapies Inc
RTW INVESTMENTS, LP has reduced its stake in Taysha Gene Therapies Inc by selling 947,158 shares, impacting its portfolio by -0.06%. Despite the reduction, RTW Investments still holds a significant 23,407,133 shares in Taysha Gene Therapies, a biotechnology company facing financial challenges and a significant stock price decline since its IPO. The move suggests a strategic reevaluation by the investment firm in light of Taysha Gene Therapies Inc.'s current financial performance and market conditions.
GSA Capital Partners LLP Increases Holdings in Taysha Gene Therapies, Inc. $TSHA
GSA Capital Partners LLP significantly increased its stake in Taysha Gene Therapies (NASDAQ:TSHA) by 969.0% in Q3, now owning 477,749 shares valued at $1.56 million. Despite this institutional accumulation, company insiders like CEO Sean Nolan and CFO Kamran Alam have recently sold a substantial number of shares, totaling over $4.5 million in the last 90 days. The stock currently holds a "Moderate Buy" rating from analysts with an average target price of $10.91, trading around $4.58 per share.
Commit To Buy Taysha Gene Therapies At $2.50, Earn 16.8% Annualized Using Options
BNK Invest suggests that investors interested in Taysha Gene Therapies Inc (TSHA) but hesitant about the current market price of $4.61/share could consider selling put options. Specifically, selling a December put at the $2.50 strike offers a premium of 35 cents, representing a 14% return against the commitment or a 16.8% annualized YieldBoost. This strategy provides a return unless the stock falls by 45.5% and the contract is exercised, resulting in a cost basis of $2.15 per share.
Here’s what analysts are saying about Taysha Gene Therapies (TSHA)
This article provides an analysis of investor sentiment and analyst ratings for Taysha Gene Therapies (TSHA). It highlights that despite recent positive developments, the company's stock has faced a downward trend. The analysis includes a detailed breakdown of price targets and recommendations from several financial analysts.
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
Taysha Gene Therapies (TSHA) announced that its Compensation Committee granted restricted stock units representing 349,000 shares to three new employees on February 2, 2026. This inducement grant, made under the company's 2023 Inducement Plan, is in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest in four equal annual installments.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies announced an inducement grant on February 2, 2026, awarding restricted stock units representing 349,000 shares to three new employees. This grant, made under the 2023 Inducement Plan, aligns with Nasdaq Listing Rule 5635(c)(4) and is a material inducement for their employment. The RSUs will vest over four equal annual installments, contingent on continued service.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. announced an inducement grant of restricted stock units (RSUs) representing 349,000 shares of common stock to three new employees. This grant, made under the 2023 Inducement Plan, is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the employees. The RSUs will vest in four equal annual installments, contingent on continued employment.
Did Rett Trial Milestones Just Shift Taysha Gene Therapies' (TSHA) Gene Therapy Approval Path Narrative?
Taysha Gene Therapies (TSHA) has achieved key clinical and regulatory milestones for its TSHA-102 Rett syndrome program, including dosing the first patient in the REVEAL pivotal phase and FDA authorization to use ASPIRE trial data for a Biologics License Application. These advancements could accelerate the gene therapy candidate's approval path, reinforcing Taysha's investment narrative despite the company's ongoing unprofitability and dependence on capital markets. Investors are advised to consider the potential for high returns balanced against risks like cash burn and share dilution.
Taysha’s REVEAL Trial Progress Puts Rett Gene Therapy And Valuation In Focus
Taysha Gene Therapies has dosed the first patient in its pivotal REVEAL trial for TSHA-102, a gene therapy for Rett syndrome, with FDA-approved trial design. The company anticipates updated safety and efficacy data in the first half of 2026, which will be a key market focus point. While the stock has seen significant returns over the past three years, it has experienced a recent decline, and Simply Wall St assesses it as trading significantly below its estimated fair value.
Taysha Gene Therapies, Inc. (TSHA) gains Wells Fargo’s support on Rett syndrome program progress
Wells Fargo has expressed support for Taysha Gene Therapies (TSHA) following positive developments in its Rett syndrome program. Despite a recent capital raise that caused a short-term stock dip, analysts are optimistic about the company's long-term prospects, especially with upcoming data readouts for multiple clinical programs. The analyst reiterated an Overweight rating and a $9 price target, citing encouraging patient data and the potential for TSHA-120 and TSHA-102 to address significant unmet medical needs.
Cell And Gene Therapy Enters ‘Disciplined Growth Cycle’ As Commercial Momentum Builds
The cell and gene therapy sector is transitioning into a "disciplined growth cycle," indicating a shift towards more stable and sustainable development. This new phase is characterized by increasing commercial momentum, suggesting that these advanced therapies are gaining wider adoption and market penetration. C-suite leaders are observing these trends, highlighting the industry's strategic evolution in life sciences.
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress
Wells Fargo has increased its price target for Taysha Gene Therapies (TSHA) from $8 to $11, maintaining an Overweight rating, due to progress in its Rett syndrome research and FDA approval of a favorable trial design. Taysha Gene Therapies also reported significant advancements in its TSHA-102 Rett syndrome program, including dosing the first patient in the REVEAL pivotal phase and FDA authorization to use ASPIRE trial data for its Biologics License Application (BLA). The company anticipates completing dosing for both studies by Q2 2026, with updated safety and efficacy data from REVEAL Part A expected in H1 2026.
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress
Taysha Gene Therapies, Inc. (TSHA) has received increased support from Wells Fargo, which raised its price target to $11 from $8 due to anticipated 2026 outperformance in its Rett syndrome research. The company also reported significant progress on its TSHA-102 Rett syndrome program, with the first patient dosed in the REVEAL pivotal phase and FDA authorization to use ASPIRE trial data in its BLA submission. TSHA plans to complete dosing in both studies by Q2 2026, with updated safety and efficacy data from REVEAL Part A expected in H1 2026.
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress
Taysha Gene Therapies, Inc. (TSHA) has received increased support from Wells Fargo due to ongoing advancements in its Rett syndrome program, TSHA-102. Wells Fargo raised its price target for TSHA to $11 from $8 and maintained an Overweight rating, citing the FDA's approval of a favorable trial design and significant progress in clinical trials. The company reported dosing the first patient in the REVEAL pivotal phase in Q4 2025 and plans to complete dosing in both studies by Q2 2026, with updated safety and efficacy data expected in H1 2026.
Pivotal Trial for Taysha's Rett Syndrome Gene Therapy TSHA-102 Doses First Patient
Taysha Gene Therapies has dosed the first patient in the pivotal phase 3 portion of its REVEAL clinical trial for TSHA-102, a gene therapy for Rett syndrome. The company also announced FDA alignment on a potential BLA strategy, which will incorporate data from a separate trial, ASPIRE, involving younger patients. This progress streamlines Taysha's path toward BLA submission, aiming to address the significant unmet medical need for Rett syndrome patients.
Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans
Taysha Gene Therapies has dosed its first patient in the pivotal phase 3 REVEAL trial for TSHA-102, a gene therapy for Rett syndrome, and has aligned with the FDA on BLA submission plans. The BLA will incorporate at least three months of safety data from three younger patients (aged 2 to less than 4 years) in the upcoming ASPIRE trial to support a broad label for patients aged 2 years and older. Previously, Part A of REVEAL demonstrated a 100% response rate in developmental milestones among adolescent and adult patients, and TSHA-102 has received FDA breakthrough therapy designation.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Moderate Buy" from Analysts
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a consensus "Moderate Buy" rating from thirteen analysts, with an average 12-month price target of $10.67. This comes despite recent insider selling, including significant share disposals by the CEO and another insider in January. The company, trading around $4.57 with a market cap of $1.25 billion, has negative earnings and institutional ownership of about 77.7%.
10 Best Strong Buy Stocks to Invest In Under $5
This article identifies top "strong buy" stocks under $5, highlighting Taysha Gene Therapies, Inc. (NASDAQ: TSHA) as a key contender. Needham has reiterated a 'Buy' rating for Taysha with a $10 price target, citing progress in its pivotal trial for Rett syndrome treatment. The company is advancing with its TSHA-102 gene therapy, with significant clinical milestones expected in 2026.
Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA)
Needham has reiterated a Buy rating and a $10 price target for Taysha Gene Therapies (TSHA) following progress in its TSHA-102 pivotal program for Rett syndrome. The company announced the dosing of the first patient in the REVEAL pivotal trial and reached alignment with the FDA for including safety data from the ASPIRE trial to support a broad label. Completion of dosing in both trials is anticipated in Q2 2026, with further efficacy data expected in H1 2026.
Kamran Alam Sells 78,968 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock
Taysha Gene Therapies CFO Kamran Alam sold 78,968 shares of the company's stock on January 23rd for approximately $375,098 and an additional 23,849 shares on January 26th for around $109,944, reducing his stake by 5.11%. The company remains unprofitable with a negative EPS and net margin, yet hedge funds and institutional investors have recently increased their positions. Wall Street analysts have a "Moderate Buy" consensus rating with an average target price of $10.67, significantly higher than its current trading price of $4.76.
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells 41,312 Shares of Stock
Taysha Gene Therapies (NASDAQ:TSHA) CEO Sean Nolan sold 41,312 shares of the company's stock on January 26th, valued at approximately $190,448. This transaction reduced his stake by 1.40% to 2,908,257 shares. The company has a market capitalization of $1.30 billion, and analysts widely rate it as a "Moderate Buy" with an average price target of $10.67.
Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells $649,747.75 in Stock
Taysha Gene Therapies CEO Sean Nolan sold 136,789 shares of TSHA stock for $649,747.75, reducing his stake by 4.43%. Despite the sale, institutional investors hold 77.7% of the stock and analysts have a "Moderate Buy" rating with an average price target of $10.67. The company, which is clinical-stage biotechnology, remains loss-making but is developing gene therapies for rare neurological diseases.
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) reported a Q1 loss of $0.08 per share, in line with Zacks Consensus Estimate, and revenue of $2.3 million, surpassing estimates by 9.62%. The company's shares have risen about 37% year-to-date, outperforming the S&P 500. Analysts currently assign TSHA a Zacks Rank #3 (Hold), indicating expected in-line market performance.
Taysha Gene Therapies commences underwritten public offering
Taysha Gene Therapies announced the commencement of an underwritten public offering of its common stock. All shares in the offering will be sold by Taysha Gene Therapies itself. The offering is subject to market and other conditions, and there is no guarantee as to its completion or terms.
Taysha Gene Therapies commences underwritten public offering
Taysha Gene Therapies has announced the commencement of an underwritten public offering of its common stock. The offering is subject to market conditions and there is no guarantee regarding its completion or terms.
Is Taysha (TSHA) Balancing TSHA-102 Trial Progress and New Equity Shelf in a Sustainable Way?
Taysha Gene Therapies (TSHA) is progressing with its TSHA-102 Rett syndrome program, having dosed the first patient in the REVEAL pivotal trial and secured FDA alignment for the ASPIRE study, anticipating a BLA submission. Concurrently, the company filed a shelf registration for approximately $87.91 million in common shares to fund its gene therapy initiatives. This dual approach aims to advance clinical development while securing financial resources, with market reaction to potential equity issuance and trial outcomes being key to future shareholder returns.
A Look At Taysha Gene Therapies (TSHA) Valuation After Key TSHA-102 Rett Syndrome Trial Milestones
Taysha Gene Therapies' (TSHA) stock is under scrutiny following key advancements in its TSHA-102 Rett syndrome trial, including dosing the first patient in the REVELA trial and FDA alignment for the ASPIRE safety trial. Despite recent share price declines, the company shows strong longer-term returns, and its current valuation suggests it may be significantly undervalued, with a narrative fair value of US$10.79 against a current trading price of US$4.90. However, the valuation's reliability depends heavily on positive REVELA trial data and timely FDA decisions.
Nagendran sells Taysha gene therapies (TSHA) stock for $942k By Investing.com
Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies (NASDAQ:TSHA), sold 200,000 shares of common stock for $942,000 on January 12, 2026, under a Rule 10b5-1 trading plan. On the same day, Sukumar also exercised options to acquire 200,000 shares and received 427,000 restricted stock units. This transaction follows the company's Q3 2025 financial results and positive analyst ratings from Raymond James, Goldman Sachs, and Citizens, all highlighting the progress of their TSHA-102 gene therapy for Rett syndrome.
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock
Taysha Gene Therapies' insider Sukumar Nagendran sold 200,000 shares of the company's stock on January 12th for $942,000, reducing his holding by 16.58%. This follows previous sales in November and December, bringing his total recent disposals to 570,172 shares worth approximately $2.64 million. Despite negative EPS and margins, analysts maintain a "Moderate Buy" rating with an average target price of $10.67 for TSHA.
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects
Taysha Gene Therapies Inc. (TSHA) is highlighted as a promising biotech, particularly for its gene therapy TSHA-102 for Rett syndrome, which has begun pivotal trials. Jefferies anticipates significant growth, projecting peak revenues of $2 billion for TSHA-102. The company focuses on developing AAV-based gene therapies for severe monogenic central nervous system disorders.
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects
Taysha Gene Therapies Inc. (NASDAQ: TSHA) is highlighted as a promising biotech stock after initiating the REVELA pivotal trial for its Rett syndrome gene therapy, TSHA-102. Jefferies reiterated Taysha as a strong growth prospect for 2026, foreseeing a potential $2 billion in peak revenue for TSHA-102. The company focuses on developing AAV-based gene therapies for central nervous system monogenic disorders.
Why Taysha Gene Therapies (TSHA) Is Down 5.1% After FDA Alignment On TSHA-102 Safety Data
Taysha Gene Therapies (TSHA) recently announced progress in its TSHA-102 Rett syndrome trial, with the first patient dosed in the REVEAL pivotal trial and FDA alignment to use ASPIRE trial safety data for its Biologics License Application. This regulatory clarity and clinical advancement are positive for the company's path to approval, though investor concerns persist regarding ongoing losses, funding needs, potential dilution from a recent shelf registration, and the uncertainty of regulatory timelines.
Assessing Taysha Gene Therapies (TSHA) Valuation After REVEAL Trial Progress And FDA Alignment On TSHA-102
Taysha Gene Therapies (TSHA) has gained attention after initiating its REVEAL pivotal trial for TSHA-102 and securing FDA alignment for its BLA submission, with its share price increasing over 170% in the last year. Despite a current trading price of US$5.31, analysts suggest the company may be undervalued, with a narrative fair value of US$10.79. However, its Price to Book ratio indicates a mixed market signal, suggesting potential overvaluation compared to the broader industry but undervaluation compared to its direct peers.
Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Chardan Capital
Chardan Capital reaffirmed a "Buy" rating for Taysha Gene Therapies (NASDAQ:TSHA) with a $12 price target, indicating a significant potential upside. Despite the positive analyst sentiment, the company remains unprofitable and recently saw an insider sell a substantial number of shares. The stock has a consensus "Moderate Buy" rating from analysts with an average target price of $10.67.
TSHA - Taysha Gene Therapies, Inc. Latest Stock News & Market Updates
This page serves as a dedicated resource for investors tracking Taysha Gene Therapies (TSHA), a clinical-stage biotechnology company focused on gene therapies for severe genetic CNS disorders. It aggregates official news, press releases, and financial updates, detailing their clinical trials, regulatory progress, and strategic initiatives. Key recent developments include progress on their TSHA-102 program for Rett syndrome, inducement grants, and financial results, highlighting their cash runway into 2028 and FDA Breakthrough Therapy designation for TSHA-102.
Taysha doses first patient in pivotal Rett syndrome gene therapy trial By Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) has enrolled the first patient in its pivotal REVEAL trial for TSHA-102, a gene therapy for Rett syndrome, with results expected in Q2 2026. The company also reached an agreement with the FDA to include safety data from younger patients in its Biologics License Application, supporting a broad label. This milestone marks significant progress for the company, which has recently received upgrades from Goldman Sachs and Citizens for its promising gene therapy.
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock
Raymond James has reiterated its "Strong Buy" rating and $13.00 price target for Taysha Gene Therapies (NASDAQ:TSHA) after the company announced clinical and regulatory progress for its TSHA-102 gene therapy for Rett syndrome. The company has dosed the first patient in the REVEAL pivotal trial and reached regulatory alignment with the FDA to include safety data from a second study in younger patients for its Biologics License Application. Despite a recent stock drop, the firm views the REVEAL trial as de-risked and expects key data by the end of 2026, with other analysts like Goldman Sachs and Citizens also expressing positive outlooks.
Taysha doses first patient in pivotal Rett syndrome gene therapy trial
Taysha Gene Therapies (NASDAQ:TSHA) has initiated its pivotal REVEAL trial for Rett syndrome, dosing the first patient with its gene therapy, TSHA-102. The company, valued at $1.34 billion, aims to complete patient dosing by Q2 2026 and has secured FDA alignment for its Biologics License Application, which will include specific safety data to support a broad label for patients aged 2 and older. Rett syndrome is a rare neurodevelopmental disorder, and Taysha is developing a one-time treatment targeting the genetic root cause using its miRNA-Responsive Auto-Regulatory Element technology.
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Taysha Gene Therapies announced significant progress in its TSHA-102 pivotal gene therapy program for Rett syndrome, including dosing the first patient in the REVEAL pivotal trial and reaching written alignment with the FDA regarding the inclusion of ASPIRE trial data for a broad label. The company expects to complete dosing in both REVEAL and ASPIRE trials in Q2 2026 and anticipates longer-term safety and efficacy data from the REVEAL Phase 1/2 trials in H1 2026. This development aims to address the genetic root cause of Rett syndrome, offering a potential redefinition of the treatment paradigm.
New gene therapy trial progresses for children and adults with Rett syndrome
Taysha Gene Therapies announced significant progress in its TSHA-102 pivotal gene therapy program for Rett syndrome, including dosing the first patient in the REVEAL trial in Q4 2025 and achieving FDA alignment to include ASPIRE trial safety data in a planned Biologics License Application (BLA). The company expects to complete dosing for both REVEAL and ASPIRE trials in Q2 2026, aiming for a broad label for patients aged two years and older. This advancement offers hope for a disease with a high unmet medical need.
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Taysha Gene Therapies announced significant progress in its TSHA-102 pivotal gene therapy program for Rett syndrome, including dosing the first patient in the REVEAL pivotal trial and aligning with the FDA on including ASPIRE trial safety data in its BLA submission. The company expects to complete dosing in both REVEAL and ASPIRE trials by Q2 2026, aiming for a broad label for patients aged two years and older. This progress streamlines Taysha's path toward a Biologics License Application for TSHA-102, which addresses the genetic root cause of Rett syndrome.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Analysts
Taysha Gene Therapies (NASDAQ:TSHA) has received a consensus "Moderate Buy" rating from thirteen analysts, with an average 12-month price target of $10.42, significantly higher than its recent open price of $5.25. Insider Sukumar Nagendran recently sold over 260,000 shares, reducing his stake by 20.53%, though insiders still own 3.78% of the company. The clinical-stage gene therapy company, despite having negative earnings, holds a market cap of $1.44 billion and a volatile 12-month trading range of $1.05 to $6.02.
Rice Hall James & Associates LLC Buys New Holdings in Taysha Gene Therapies, Inc. $TSHA
Rice Hall James & Associates LLC has acquired a new stake in Taysha Gene Therapies, purchasing 578,118 shares valued at approximately $1.89 million in the third quarter of this year. This makes them owners of about 0.21% of the company's stock. Insider Sukumar Nagendran recently sold a significant portion of his holdings, reducing his ownership by over 20%.
Taysha Gene Therapies stock hits 52-week high at $5.98 By Investing.com
Taysha Gene Therapies Inc. (TSHA) stock reached a new 52-week high of $5.98, reflecting a significant 208.65% growth over the past year and underscoring strong investor confidence. This surge follows positive developments like meeting EPS expectations in Q3 2025, promising clinical trial results for its Rett syndrome gene therapy, and favorable analyst upgrades from Goldman Sachs and Citizens. The company is positioned as a key player in the biotechnology field with its TSHA-102 gene therapy for Rett syndrome entering Phase 3 development.
Taysha Gene Therapies stock hits 52-week high at $5.98
Taysha Gene Therapies Inc. (TSHA) stock reached a 52-week high of $5.98, reflecting a significant 208.65% growth over the past year. This achievement is bolstered by recent positive news, including meeting EPS expectations for Q3 2025, a Buy rating upgrade from Goldman Sachs due to promising TSHA-102 gene therapy trial results, and Citizens raising its price target to $8.00. These developments highlight strong investor confidence and the company's advancements in the gene therapy sector, particularly for Rett syndrome.
Taysha Gene Therapies stock hits 52-week high at $5.98 By Investing.com
Taysha Gene Therapies Inc. (TSHA) reached a 52-week high of $5.98, reflecting a 208.65% increase over the past year and underscoring investor confidence in its gene therapy pipeline. Recent positive developments include meeting third-quarter EPS expectations, promising clinical trial results for its Rett syndrome gene therapy (TSHA-102), a Goldman Sachs upgrade to Buy, and Citizens raising its price target to $8.00. These factors highlight the company's significant progress and market appeal in the biotechnology sector.
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program
Taysha Gene Therapies Inc (TSHA) is trading near its 52-week high, driven by advancements in its Rett syndrome program and a "Buy" upgrade from Goldman Sachs with an $11 price target. The company received FDA Breakthrough Therapy Designation for TSHA-102 and finalized its REVEAL trial protocol, including a six-month interim analysis that could support a future Biologics License Application. Taysha also regained full rights to TSHA-102, enhancing strategic flexibility and contributing to regulatory clarity and market optimism.
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is trading near its 52-week high after Goldman Sachs upgraded the stock to "Buy" with an $11 price target, citing optimism around its TSHA-102 Rett syndrome program. The company recently received FDA Breakthrough Therapy Designation for TSHA-102 and regained full rights to the program, signaling strong clinical and regulatory momentum. Taysha Gene aims to develop gene therapy treatments for severe central nervous system genetic diseases.
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock By Investing.com
Citizens has maintained its Market Outperform rating and $8.00 price target on Taysha Gene Therapies (NASDAQ:TSHA), citing promising outlooks for both Taysha and Neurogene (NGNE) as they advance to registrational studies. The analyst highlighted that these studies are well-designed, focusing on objective clinical benefit measurements. Meanwhile, Neurogene has also seen positive analyst attention, with plans to initiate a registrational trial for NGN-401 for Rett syndrome and increased price targets from other firms.
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 1-Year High - Time to Buy?
Taysha Gene Therapies (NASDAQ:TSHA) reached a new 52-week high of $5.95, trading above its 50- and 200-day moving averages, attracting a "Moderate Buy" consensus rating with a $10.42 target price from analysts. Despite positive institutional investor ownership at 77.7% and several analyst upgrades, concerns persist with weak fundamentals, including negative EPS and ROE, alongside a significant insider share sale. The company specializes in developing gene therapies for central nervous system monogenic diseases, with several key product candidates in its pipeline.
